Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary L Disis

Showing results (91-100 of 189) with videos related to

Pageof 19
Sort By:
Clinical Immunology (Orlando, Fla.)|October 5, 2007
Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancersLupe G Salazar, Andrew L Coveler, Ron E Swensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo primingYushe Dang, Keith L Knutson, Vivian Goodell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II allelesLupe G Salazar, John Fikes, Scott Southwood, et al.
Cancer Immunology, Immunotherapy : CII|February 9, 2010
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphataseBrian M Olson, Thomas P Frye, Laura E Johnson, et al.
Cancer Research|April 30, 2014
Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activityDenise L Cecil, Gregory E Holt, Kyong Hwa Park, et al.
Clinical and Translational Science|December 21, 2012
Values in translation: how asking the right questions can move translational science toward greater health impactMaureen Kelley, Kelly Edwards, Helene Starks, et al.
Breast Cancer Research and Treatment|June 11, 2013
T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposityDenise L Cecil, Kyong Hwa Park, Ekram Gad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2002
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccinesMary L Disis, Theodore A Gooley, Kristine Rinn, et al.
Journal for Immunotherapy of Cancer|September 15, 2022
Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine modelJinho Kang, Hye-Jin Lee, Jimin Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancerVivian Goodell, Lupe G Salazar, Nicole Urban, et al.
Pageof 19

Showing results (91-100 of 189) with videos related to

Sort By:
Pageof 19
Clinical Immunology (Orlando, Fla.)|October 5, 2007
Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancersLupe G Salazar, Andrew L Coveler, Ron E Swensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo primingYushe Dang, Keith L Knutson, Vivian Goodell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II allelesLupe G Salazar, John Fikes, Scott Southwood, et al.
Cancer Immunology, Immunotherapy : CII|February 9, 2010
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphataseBrian M Olson, Thomas P Frye, Laura E Johnson, et al.
Cancer Research|April 30, 2014
Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activityDenise L Cecil, Gregory E Holt, Kyong Hwa Park, et al.
Clinical and Translational Science|December 21, 2012
Values in translation: how asking the right questions can move translational science toward greater health impactMaureen Kelley, Kelly Edwards, Helene Starks, et al.
Breast Cancer Research and Treatment|June 11, 2013
T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposityDenise L Cecil, Kyong Hwa Park, Ekram Gad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2002
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccinesMary L Disis, Theodore A Gooley, Kristine Rinn, et al.
Journal for Immunotherapy of Cancer|September 15, 2022
Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine modelJinho Kang, Hye-Jin Lee, Jimin Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancerVivian Goodell, Lupe G Salazar, Nicole Urban, et al.
Pageof 19